Evidence map›Paper›PMID 42350616›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2026

Comparison of [

Anniina Hyväkkä, Marko Seppänen, Maria Sundvall, Veera Sivonen, Kalle Mattila, Mikael Anttinen, Otto Ettala, Mikael Högerman, Anna Kirjavainen, Olli Eskola and 7 more

Abstract readClinical TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Anniina HyväkkäDepartment of Oncology and FICAN West Cancer Center, University of Turku and Turku University Hospital, Turku, Finland.ORCID http://orcid.org/0000-0002-0732-2788
Marko SeppänenDepartment of Clinical Physiology, Nuclear Medicine and Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland.ORCID http://orcid.org/0000-0003-1122-2445
Maria SundvallDepartment of Oncology and FICAN West Cancer Center, University of Turku and Turku University Hospital, Turku, Finland.ORCID http://orcid.org/0000-0002-0494-2965
Veera SivonenDepartment of Oncology and FICAN West Cancer Center, University of Turku and Turku University Hospital, Turku, Finland.
Kalle MattilaDepartment of Oncology and FICAN West Cancer Center, University of Turku and Turku University Hospital, Turku, Finland.ORCID http://orcid.org/0000-0002-9688-9187
Mikael AnttinenDepartment of Urology, University of Turku and Turku University Hospital, Turku, Finland.ORCID http://orcid.org/0000-0002-9351-7177
Otto EttalaDepartment of Urology, University of Turku and Turku University Hospital, Turku, Finland.ORCID http://orcid.org/0000-0003-1011-4602
Mikael HögermanDepartment of Urology, University of Turku and Turku University Hospital, Turku, Finland.ORCID http://orcid.org/0000-0002-4287-9231
Anna KirjavainenRadiopharmaceutical Chemistry, Turku PET Centre, University of Turku, Turku, Finland.ORCID http://orcid.org/0000-0003-3981-2973
Olli EskolaRadiopharmaceutical Chemistry, Turku PET Centre, University of Turku, Turku, Finland.ORCID http://orcid.org/0000-0002-9874-5662
Sarita ForsbackRadiopharmaceutical Chemistry, Turku PET Centre, University of Turku, Turku, Finland.ORCID http://orcid.org/0000-0002-6286-7895
Virva SaunavaaraDepartment of Medical Physics and Turku PET Centre, Turku University Hospital, Turku, Finland.ORCID http://orcid.org/0000-0001-7858-5924
Samuli ArvolaDepartment of Clinical Physiology, Nuclear Medicine and Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland.ORCID http://orcid.org/0000-0002-9696-0510
Kusti KilpinenInstitute of Biomedicine, University of Turku, Turku, Finland.
Pekka TaimenInstitute of Biomedicine, University of Turku, Turku, Finland.ORCID http://orcid.org/0000-0001-8849-4604
Simona MalaspinaDepartment of Clinical Physiology, Nuclear Medicine and Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland.ORCID http://orcid.org/0000-0002-2701-8978
Heikki MinnDepartment of Oncology and FICAN West Cancer Center, University of Turku and Turku University Hospital, Turku, Finland. heikki.minn@utu.fi.ORCID http://orcid.org/0000-0002-5878-4333

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare prostate-specific membrane antigen (PSMA) and fibroblast activation-protein inhibitor (FAPI) targeted PET/CT imaging to assess possible theranostic combination strategies of both tracers in metastatic prostate cancer (mPC).

methodsThis prospective study enrolled patients with mPC who underwent long-axial field-of-view whole-body PET/CT with

resultsA total of 1365 lesions were identified in 39 patients.

conclusionIn mPC, PSMA PET/CT remains the preferred molecular imaging method. Our findings suggest only a limited role of FAPI radioligand therapy. FAPI theranostics should focus on patients with visceral metastases and specific histological subtypes beyond acinar adenocarcinoma. CLINICAL

trial registrationEUDRACT: 2022-003788-13. Registered 21 September 2023.

Indexed as

LysinePositron Emission Tomography Computed TomographyProstatic NeoplasmsTyrosineUreaAgedAged, 80 and overAntigens, SurfaceFibroblast Activation Protein AlphaFluorine RadioisotopesGlutaratesHumansMaleMembrane ProteinsMiddle AgedNeoplasm MetastasisAntigens, SurfaceFibroblast Activation Protein AlphaFluorine RadioisotopesGlutaratesLysineMembrane ProteinspiflufolastatPyridinesRadiopharmaceuticalsTyrosineUrea18F-DCFPyL18F-FAPI-74Fibroblast activation protein (FAP)PET/CT.Prostate cancerProstate-specific membrane antigen (PSMA)

Identifiers

PMID42350616
PMCPMC13633354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.